ImmuCell (NASDAQ:ICCC) Releases Quarterly Earnings Results

ImmuCell (NASDAQ:ICCC) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.05, FiscalAI reports. The company had revenue of $8.04 million during the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a return on equity of 2.69% and a net margin of 2.57%.

ImmuCell Trading Up 4.1%

Shares of ICCC traded up $0.42 during midday trading on Friday, hitting $10.64. The stock had a trading volume of 16,534 shares, compared to its average volume of 21,728. The business has a 50-day simple moving average of $10.08 and a two-hundred day simple moving average of $9.01. The firm has a market cap of $96.63 million, a P/E ratio of 133.02 and a beta of 0.61. The company has a current ratio of 4.75, a quick ratio of 2.71 and a debt-to-equity ratio of 0.22. ImmuCell has a fifty-two week low of $4.52 and a fifty-two week high of $12.10.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered ImmuCell from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, November 4th. One analyst has rated the stock with a Hold rating. According to data from MarketBeat, the company has a consensus rating of “Hold”.

ImmuCell Company Profile

ImmuCell Corporation is a biotechnology and animal health company headquartered in Portland, Maine. The company develops, manufactures, and commercializes products designed to support the health and productivity of livestock, with a primary focus on cattle. ImmuCell’s products include FirstStep Calf Health, an on-farm diagnostic test that helps dairy and beef producers assess whether newborn calves have received adequate passive immunity from colostrum. The company also develops antibody-based products intended to help prevent or manage common diseases affecting young livestock, including neonatal calf diarrhea.